Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for paclitaxel-induced neuropathy in breast cancer patients
IRCT20180805040700N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing Duloxetine with Placebo (2 arms). Primary endpoint: Neuropathy. Started Sep 2018; status: completed.
02
Drugs
duloxetine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on IRCT20180805040700N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180805040700N1.